CURRENT APPROACHES FOR HPV-ASSOCIATED CIN
Main Article Content
Abstract
The aim of the study was to determine the frequency of expression of р16/Ki-67 in the cervical epithelium of patients with HPV-associated CIN of various degrees according to immunocytochemical studies in comparison with patients without cervical pathology.
Materials and methods. The study included 62 women with cervical HPV infection and 13 women in the control group. Patients with CIN 1 formed the 1st main group (n = 21), women with CIN2-CIN3 – the 2nd main group (n = 26), and the comparison group consisted of patients with latent HPV infection (n = 15). Research methods: liquid сytology, colposcopic, histological research; methods for determining HPV BP DNA; immunocytochemical research to determine the double staining of р16/Ki-67 markers, statistical analysis.
Results. Against the background of HPV infection, both in the 1st main group of patients with CIN1 and in the comparison group of patients with NILM, isolated cases of double staining of P16 and Ki-67 markers were recorded without significant differences between the groups (p = 0.44). In the 2nd main group of patients with CIN2, CIN3, co-expression of p16 and Ki-67 was observed in every second woman, it dominated relative to the 1st group and the comparison group (p = 0.003, p = 0.005, respectively). In the absence of HPV, the control group found that there was no double staining of markers.
Conclusion. There were no differences in coexpression in CIN1 compared to latent HPV infection and the control group. When CIN 2+ is associated with HPV BP, the frequency of immunocytochemical confirmation of P16/Ki-67 expression is increased compared to CIN1, which increases the risk of precancerous progression. When choosing a differentiated management strategy for рatients with CIN on the background of HPV, it is necessary to take into account the data of the proliferative potential of the cervical epithelium.
Downloads
Article Details
Issue
Section
References
State of cancer care in Russia in 2018 /Ed. by AD. Kaprin, VV Starinsky, and GV Petrova. M.: 2019. 236 р. Russian (Состояние онкологической помощи населению России в 2018 году /Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 236 с.)
Klinyshkova TV, Turchaninov DV, Buyan MS. Cervical cancer in the Omsk Region: epidemiological aspects. Obstetrics and Gynecology. 2018; 3: 102-108. Russian (Клинышкова Т.В., Турчанинов Д.В., Буян М.С. Эпидемиологические аспекты рака шейки матки в Омской области //Акушерство и гинекология. 2018. № 3. С. 102-108)
Wentzensen N, Arbyn M, Berkhof J, Bower M, Canfell K, Einstein M et al. Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. Int J Cancer. 2017; 140(10): 2192-2200
Prilepskaya VN. HPV-associated cervical diseases: screening, methods of examination, principles of treatment. Gynecology. 2019; 21(3): 6-8. Russian (Прилепская В.Н. ВПЧ-ассоциированные заболевания шейки матки: скрининг, методы обследования, принципы лечения //Гинекология. 2019. Т. 21, № 3. С. 6-8)
Klinishkova TV, Karatyuk TI, Mozgovoy SI, Pritykina TV. Features of expression of P16ink4α and metabolites of estradiol in HPV-associated squamous lesions of the cervix. Questions of gynecology, obstetrics and perinatology. 2011; 10 (2): 45- 49. Russian (Клинышкова Т.В., Каратюк Т.И., Мозговой С.И., Притыкина Т.В. Особенности экспрессии р16 ink4α и метаболитов эстрадиола при ВПЧ-ассоциированных плоскоклеточных поражениях шейки матки //Вопросы гинекологии, акушерства и перинатологии. 2011. Т. 10, № 2. С. 45-49)
Carozzi F, Gillio-Tos A, Confortini M, Mistro AD, Sani C, Marco LD et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2013; 14(2): 168-76
Wright TC Jr, Behrens CM, Ranger-Moore J, Rehm S, Sharma A, Stoler MH, Ridder R. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial. Gynecol Oncol. 2017; 144(1): 51-56
Wentzensen N, Fetterman B, Castle PhE, Schiffman M, Wood ShN, Stiemerling E et al. p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. Journal of the National Cancer Institute. 2015; 107(12): djv257
Gustinucci D, Giorgi Rossi P, Cesarini E, Broccolini M, Bulletti S, Carlani A et al. Use of Cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to Define the Management of Human Papillomavirus (HPV)-Positive Women in Cervical Cancer Screening. Am J Clin Pathol. 2016; 145(1): 35-45
Benevolo M, Allia E, Gustinucci D, Rollo F, Bulletti S, Cesarini E et al. Interobserver reproducibility of cytologic p16INK4a /Ki-67 dual immunostaining in human papillomavirus-positive women. Сancer Cytopathol. 2017; 125(3): 212-220
Peeters E, Wentzensen N, Bergeron C, Arbyn M. Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology. Cancer Cytopathol. 2019; 127(3): 169-180